Jimandin

Sitagliptin, the active ingredient in Jimandin, is a DPP‑4 inhibitor presented as a tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

GNH USA supplies Jimandin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Sitagliptin, a DPP‑4 inhibitor, is used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): improves blood glucose levels when combined with diet and exercise. - Type 2 diabetes mellitus (add‑on to metformin): enhances glycaemic control alongside metformin therapy. - Type 2 diabetes mellitus (add‑on to insulin): provides additional glucose lowering when used with insulin regimens.

Sitagliptin may be associated with several adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Nasopharyngitis - Headache - Upper respiratory tract infection - Gastrointestinal discomfort (e.g., nausea, abdominal pain)

Serious or Rare Side Effects: - Acute pancreatitis - Severe allergic reactions (e.g., angioedema, anaphylaxis) - Bullous skin disorders (e.g., bullous pemphigoid)

When prescribing sitagliptin, clinicians should consider several precautionary measures to ensure patient safety.

- Renal function: assess kidney function before initiating and adjust dose if impairment is present. - Cardiovascular disease: monitor for signs of heart failure, especially in patients with existing cardiac conditions. - Hypersensitivity: discontinue the drug promptly if any allergic reaction such as rash or swelling occurs. - Pancreatitis: advise patients to report persistent abdominal pain, as it may indicate pancreatic inflammation. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase sitagliptin plasma concentrations, raising risk of adverse effects. - Insulin secretagogues (e.g., sulfonylureas): combined use can heighten risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: may alter glucose control; monitor blood sugar regularly. - ACE inhibitors: concurrent use warrants renal function monitoring. - Rifampin: can reduce sitagliptin exposure, potentially diminishing its glucose‑lowering effect.